Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3521491 | 0.85 | TDP1 (0.56) | ALDH1A1LMNATDP1L3MBTL1CYP1A2 | |
| SCHEMBL8544715 | 0.79 | GSK3A (0.47) | ALDH1A1LMNATDP1L3MBTL1CYP1A2 | |
| SCHEMBL12692930 | 0.78 | KDM4E (0.66) | ALDH1A1LMNAL3MBTL1CYP3A4HPGD | |
| SCHEMBL25271993 | 0.78 | GSK3A (0.46) | ALDH1A1LMNATDP1L3MBTL1CYP1A2 | |
| SCHEMBL9354106 | 0.77 | ALDH1A1 (0.67) | ALDH1A1LMNAHSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL8603151 | 0.77 | ALDH1A1 (0.67) | ALDH1A1L3MBTL1HPGDGFERPOLB | |
| SCHEMBL13902978 | 0.76 | AGTR1 (0.55) | ALDH1A1LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7834131 | 0.75 | HPGD (0.50) | ALDH1A1LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL3285126 | 0.75 | ALDH1A1 (0.50) | ALDH1A1LMNACYP1A2CYP3A4CYP2C9 | |
| SCHEMBL5426939 | 0.75 | PDE2A (0.46) | ALDH1A1LMNATDP1L3MBTL1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858636-B2 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G.D. SEARLE & CO. (US) | 2005-02-22 | — | — | US | disclosed |
| US-20040048911-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | G. D. SEARLE & CO. | 2004-03-11 | — | — | US | disclosed |
| US-6492397-B1 | SUCH AS 1-PROPYL-4-BUTYL-1,3-DIHYDRO-3-((5-(2-(1H-TETRAZOL-5-YL)PHENYL)-2 -PYRIDINYL)METHYL)-2H-IMIDAZOL-2-ONE; ANGIO-TENSIN II ANTAGONISTS; CIRCULATORY DISORDERS; HYPERTENSION, CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION | 2002-12-10 | — | — | US | disclosed |
| US-20010020100-A1 | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders | G.D. SEARLE & CO. (US) | 2001-09-06 | — | — | US | disclosed |
| US-6090828-A | ARTHERIOSCLEROSIS | REITZ DAVID B (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0690854-B1 | 1-PHENYL-IMIDAZOL-2-ONE BIPHENYLMETHYL COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 2000-07-12 | — | — | EP | disclosed |
| EP-0664802-B1 | N-ARYLHETEROARYLALKYL 1-PHENYL-IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 2000-03-15 | — | — | EP | disclosed |
| EP-0978515-A2 | 1-(substituted phenyl)-4-biphenylmethyl-imidazol-2-one derivatives, their preparation and their use as angiotensin II antagonists | G.D. SEARLE & CO. (US) | 2000-02-09 | — | — | EP | disclosed |
| EP-0579766-B1 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | SEARLE & CO (US) | 1999-06-02 | — | — | EP | disclosed |
| EP-0508393-B1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | SEARLE & CO (US) | 1999-06-02 | — | — | EP | disclosed |
| US-5238952-A | Treating glaucoma disorders | G. D. SEARLE & CO. (US) | 1993-08-24 | — | — | US | disclosed |
| US-5196537-A | Angiotensin/II/ antagonists; hypotensive agents | G. D. SEARLE & CO. (US) | 1993-03-23 | — | — | US | disclosed |
| US-5164403-A | Hypotensive agents, cardiovascular disorders | G. D. SEARLE & CO. (US) | 1992-11-17 | — | — | US | disclosed |
| WO-1992017469-A2 | N-ARYLHETEROARYLALKYL IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-15 | — | — | WO | disclosed |
| EP-0508393-A1 | N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-10-14 | — | — | EP | disclosed |
| WO-1992016523-A1 | 5-ARYLHETEROARYLALKYL-1,3,5-TRISUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-10-01 | — | — | WO | disclosed |
| EP-0504888-A1 | 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | disclosed |
| US-5140036-A | Hypotensive agents; congestive heart failure; angiotensin antagonists | G. D. SEARLE & CO. (US) | 1992-08-18 | — | — | US | disclosed |
| WO-1992007834-A1 | N-SUBSTITUTED IMIDAZOL-2-ONE COMPOUNDS FOR TREATMENT OF CIRCULATORY DISORDERS | G.D. SEARLE & CO. (US) | 1992-05-14 | — | — | WO | disclosed |
| US-5087634-A | N-substituted imidazol-2-one compounds for treatment of circulatory disorders | G. D. SEARLE & CO. (US) | 1992-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020100-A1 | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders | NR3C2, AGTR1, PAH | ALDH1A1 3240/4885LMNA 965/4885TDP1 1299/4885 |
| US-20040048911-A1 | 1-phenyl imidazol-2-one biphenylmethyl compounds for treatment of circulatory disorders | AGTR1, AGTR2, REN | ALDH1A1 579/4885LMNA 1461/4885TDP1 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.